Your browser doesn't support javascript.
loading
Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern
Kevin K. Arien; Leo Heyndrickx; Johan Michiels; Katleen Vereecken; Kurt Van Lent; Sandra Coppens; Pieter Pannus; Geert A. Martens; Marjan Van Esbroeck; Maria E. Goossens; Arnaud Marchant; Koen Bartholomeeusen; Isabelle Desombere.
Afiliación
  • Kevin K. Arien; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Leo Heyndrickx; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Johan Michiels; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Katleen Vereecken; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Kurt Van Lent; Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Sandra Coppens; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Pieter Pannus; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium
  • Geert A. Martens; Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium
  • Marjan Van Esbroeck; Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Maria E. Goossens; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium
  • Arnaud Marchant; Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Universite libre de Bruxelles (ULB), Gosselies, Belgium
  • Koen Bartholomeeusen; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  • Isabelle Desombere; Immune response, SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268316
ABSTRACT
We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in healthy individuals pre-infected or not with SARS-CoV-2 and immunized with three doses of the BNT162b2 vaccine. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.
Licencia
cc_by_nc_nd
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint